Current status of superparamagnetic iron oxide contrast agents for liver magnetic resonance imaging

World J Gastroenterol. 2015 Dec 21;21(47):13400-2. doi: 10.3748/wjg.v21.i47.13400.

Abstract

Five types of superparamagnetic iron oxide (SPIO), i.e. Ferumoxides (Feridex(®) IV, Berlex Laboratories), Ferucarbotran (Resovist(®), Bayer Healthcare), Ferumoxtran-10 (AMI-227 or Code-7227, Combidex(®), AMAG Pharma; Sinerem(®), Guerbet), NC100150 (Clariscan(®), Nycomed,) and (VSOP C184, Ferropharm) have been designed and clinically tested as magnetic resonance contrast agents. However, until now Resovist(®) is current available in only a few countries. The other four agents have been stopped for further development or withdrawn from the market. Another SPIO agent Ferumoxytol (Feraheme(®)) is approved for the treatment of iron deficiency in adult chronic kidney disease patients. Ferumoxytol is comprised of iron oxide particles surrounded by a carbohydrate coat, and it is being explored as a potential imaging approach for evaluating lymph nodes and certain liver tumors.

Keywords: Eovist; Gd-EOB-DTPA; Hepatocellular carcinoma; Liver; Magnetic resonance imaging; Primovist; Resovist; Superparamagnetic iron oxide.

Publication types

  • Letter
  • Comment

MeSH terms

  • Contrast Media*
  • Dextrans
  • Gadolinium DTPA*
  • Humans
  • Iron
  • Magnetic Resonance Imaging
  • Magnetite Nanoparticles
  • Oxides

Substances

  • Contrast Media
  • Dextrans
  • Magnetite Nanoparticles
  • Oxides
  • Iron
  • Gadolinium DTPA